Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924945 · ClinicalTrials.gov registry record · NA
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
A NA study, sponsored by Masimo Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT05924945: Clinical Trial NA study, sponsored by Masimo Corporation.
NCT05924945 is a NA study that was terminated before completion, run by Masimo Corporation. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05924945, a NA study, was terminated before completion, sponsored by Masimo Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
Primary Outcome
The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale designed to be administered by a clinician. This tool can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score for the complete scale can be used to help clinicians determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. Score Range: The COWS score can range from
Interventions
- DEVICE Bridge™ active device
- DEVICE Bridge™ sham device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2024-08-19 |
| Phase | NA |
Why NCT05924945 stopped before completion
NCT05924945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Bridge™ active device is the first listed.
NCT05924945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05924945 about?
NCT05924945 is a clinical study titled "Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms". The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
What is the current status of trial NCT05924945?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2023-06-08. Estimated completion is 2024-08-19.
What interventions are being tested in trial NCT05924945?
The interventions under investigation include: Bridge™ active device (DEVICE), Bridge™ sham device (DEVICE).
Who is sponsoring clinical trial NCT05924945?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05924945's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI